Filing Flows › Comparisons › BIOA vs LGVN
BioAge Labs vs Longeveron: BIOA and LGVN compared
BioAge Labs is the larger company: $298K of revenue in its latest quarter (Q3 2026) against $287K for Longeveron (Q2 2026). Longeveron is growing faster (-9% against -86% a year earlier).
Where the money goes: BIOA and LGVN
BioAge Labs (BIOA) · Q3 2026
BioAge Labs, Q3 2026: revenue $298K (-86% year over year), net loss $33.5M, operating cash flow −$31.0M. The chart follows the revenue to costs, profit and cash.
Longeveron (LGVN) · Q2 2026
Longeveron, Q2 2026: revenue $287K (-9% year over year), net loss $6.1M, operating cash flow −$5.7M. The chart follows the revenue to costs, profit and cash.
| BioAge Labs (BIOA) | Longeveron (LGVN) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q2 2026 |
| Revenue | $298K | $287K |
| Revenue growth, Y/Y | -86% | -9% |
| Operating margin | n/m | n/m |
| Net earnings | −$33.5M | −$6.1M |
| Operating cash flow | −$31.0M | −$5.7M |
Questions
Which is bigger, BioAge Labs or Longeveron?
BioAge Labs is the larger company: $298K of revenue in its latest quarter (Q3 2026) against $287K for Longeveron (Q2 2026).
Is BioAge Labs or Longeveron growing faster?
Longeveron is growing faster (-9% against -86% a year earlier).
More: BioAge Labs earnings · how BioAge Labs makes money · Longeveron earnings · how Longeveron makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 5, 2026; 10-Q filed Aug 12, 2026). Fiscal quarters can end on different dates. Not investment advice.